MX2020009349A - Método para el tratamiento de la hipoglucemia posprandial. - Google Patents

Método para el tratamiento de la hipoglucemia posprandial.

Info

Publication number
MX2020009349A
MX2020009349A MX2020009349A MX2020009349A MX2020009349A MX 2020009349 A MX2020009349 A MX 2020009349A MX 2020009349 A MX2020009349 A MX 2020009349A MX 2020009349 A MX2020009349 A MX 2020009349A MX 2020009349 A MX2020009349 A MX 2020009349A
Authority
MX
Mexico
Prior art keywords
treating post
prandial hypoglycemia
hypoglycemia
prandial
postprandial hypoglycemia
Prior art date
Application number
MX2020009349A
Other languages
English (en)
Inventor
William Wilkison
Bentley Cheatham
James T Green
Original Assignee
Avolynt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avolynt filed Critical Avolynt
Publication of MX2020009349A publication Critical patent/MX2020009349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente memoria se revelan métodos, compuestos del transportador de glucosa dependiente de sodio (SGLT)1 y composiciones para el tratamiento de la hipoglucemia posprandial, la hipoglucemia posprandial que ocurre como una consecuencia de la cirugía gástrica.
MX2020009349A 2018-03-28 2019-03-28 Método para el tratamiento de la hipoglucemia posprandial. MX2020009349A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649352P 2018-03-28 2018-03-28
PCT/US2019/024463 WO2019191352A1 (en) 2018-03-28 2019-03-28 Method for treating post-prandial hypoglycemia

Publications (1)

Publication Number Publication Date
MX2020009349A true MX2020009349A (es) 2021-04-28

Family

ID=68060762

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009349A MX2020009349A (es) 2018-03-28 2019-03-28 Método para el tratamiento de la hipoglucemia posprandial.

Country Status (7)

Country Link
US (1) US11596644B2 (es)
EP (1) EP3773546A4 (es)
CN (1) CN112469407A (es)
BR (1) BR112020019624A8 (es)
CA (1) CA3094118A1 (es)
MX (1) MX2020009349A (es)
WO (1) WO2019191352A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
BRPI0821773B8 (pt) 2007-12-27 2021-05-25 Kissei Pharmaceutical monossebacato cristalino de bis[3-(3-{4-[3-(beta-dglicopiranosilóxi)-5-isopropil-1h-pirazol-4-ilmetil]-3-metilfenóxi}propilamino)-2,2-dimetil-propionamida], composição farmacêutica e medicamento compreendendo o dito composto
CA2725230C (en) 2008-04-16 2016-05-17 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US20150005233A1 (en) * 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
US9273085B2 (en) 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
WO2014081660A1 (en) 2012-11-20 2014-05-30 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1

Also Published As

Publication number Publication date
EP3773546A4 (en) 2022-02-23
US11596644B2 (en) 2023-03-07
BR112020019624A8 (pt) 2022-03-03
US20210085701A1 (en) 2021-03-25
WO2019191352A1 (en) 2019-10-03
CA3094118A1 (en) 2019-10-03
WO2019191352A9 (en) 2019-11-28
BR112020019624A2 (pt) 2021-01-05
EP3773546A1 (en) 2021-02-17
CN112469407A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12020550901A1 (en) Macrocyclic compounds for treating disease
IL285782A (en) Compounds, compositions, and methods for treating disease
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
MX2022008744A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
MX2021015235A (es) Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni.
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
WO2018189661A3 (en) Methods and compounds for treating diabetes
IL288864A (en) Treatment that includes sglt inhibitors, for example sglt 1/2 inhibitors
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020009349A (es) Método para el tratamiento de la hipoglucemia posprandial.
MX2021008716A (es) Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina.
EP3946433A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF FABRY'S DISEASE
WO2016196373A8 (en) Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
EP3826629A4 (en) METHODS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER USING 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
MX2021012152A (es) Metodos para el tratamiento de beta-talasemia.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.